Axogen, Inc. (LON:0HKD)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.61B +200.7% |
| Revenue (ttm) | 180.32M +22.4% |
| Net Income | -23.82M |
| EPS | -0.50 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 67.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 902 |
| Open | 41.42 |
| Previous Close | 41.26 |
| Day's Range | 40.49 - 41.42 |
| 52-Week Range | 9.29 - 51.00 |
| Beta | 1.17 |
| RSI | 57.67 |
| Earnings Date | Apr 28, 2026 |
About Axogen
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstr... [Read more]
Financial Performance
In 2025, Axogen's revenue was $225.21 million, an increase of 20.21% compared to the previous year's $187.34 million. Losses were -$15.70 million, 57.6% more than in 2024.
Financial numbers in USD Financial StatementsNews
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla.
AxoGen price target raised to $48 from $41 at Raymond James
Raymond James raised the firm’s price target on AxoGen (AXGN) to $48 from $41 and keeps an Outperform rating on the shares. Axogen is delivering its strongest growth in five…
AxoGen price target raised to $50 from $45 at Canaccord
Canaccord analyst Caitlin Roberts raised the firm’s price target on AxoGen (AXGN) to $50 from $45 and keeps a Buy rating on the shares. The firm said they posted an…
AxoGen price target raised to $50 from $39 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on AxoGen (AXGN) to $50 from $39 and keeps a Buy rating on the shares following the Q1 sales beat. AxoGen is an…
AxoGen price target raised to $50 from $42 at Citizens
Citizens raised the firm’s price target on AxoGen (AXGN) to $50 from $42 and keeps an Outperform rating on the shares. The bullish view on AxoGen is driven by its…
Axogen Earnings Call Transcript: Q1 2026
Revenue grew 26.6% year-over-year to $61.5M in Q1 2026, with strong double-digit growth across all markets and expanded commercial coverage. Full-year guidance was raised to at least $270M revenue and 74%-76% gross margin, with continued investment in sales force and innovation.
AxoGen raises FY26 revenue view to $270M from $265.7M, consensus $265.89M
The company said, “We expect 2026 revenue growth to be at least 20%, or $270 million, for the full-year and gross margin to be in the range of 74% to…
AxoGen reports Q1 adjusted EPS 7c, consensus 7c
Reports Q1 revenue $61.46M, consensus $57.77M. “We are pleased with our first-quarter revenue performance and the progress we’re making across each of Axogen’s (AXGN) strategic plan priorities,” said ...
Axogen, Inc. Reports First Quarter 2026 Financial Results
ALACHUA, Fla. and TAMPA, Fla.
AxoGen price target raised to $45 from $40 at Canaccord
Canaccord raised the firm’s price target on AxoGen (AXGN) to $45 from $40 and keeps a Buy rating on the shares. The firm updated its model heading ito Q1 results.
AxoGen price target raised to $50 from $40 at Lake Street
Lake Street raised the firm’s price target on AxoGen (AXGN) to $50 from $40 and keeps a Buy rating on the shares. Anthem and Cigna recently issued positive coverage policies…
AxoGen jumps after Cigna picks up Avance nerve graft
Shares of AxoGen (AXGN) moved higher after Cigna (CI) added coverage for the company’s nerve graft. AxoGen’s Avance Nerve Graft “is considered medically necessary when used in association with mastect...
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
ALACHUA, Fla. and TAMPA, Fla.
Axogen Transcript: The Citizens Life Sciences Conference 2026
Achieved broad BLA label and 12 years of exclusivity, enabling continued market leadership in nerve care. Insurance coverage is expanding, with all technical requirements met for major payers, and CMS reimbursement has improved. Growth strategies focus on education, targeted accounts, and expanding the sales force.
Axogen Transcript: Leerink Global Healthcare Conference 2026
Validated business models and double-digit growth across all segments are driving expansion, with a strengthened balance sheet and at least 18% top-line growth targeted for 2026. Regulatory milestones and reimbursement wins set the stage for operational efficiencies and broader market access.
Axogen Transcript: 47th Annual Raymond James Institutional Investor Conference
Focused on making peripheral nerve restoration a standard of care, the company targets growth in extremities, breast, and oral maxillofacial markets, with prostate care in development. Recent BLA approval for AVANCE supports payer coverage and operational improvements, while strong financials and a recent capital raise position the company for continued expansion.
Axogen Earnings Call Transcript: Q4 2025
Revenue grew 20% year-over-year with strong double-digit growth across all markets and a key FDA BLA approval for Avance. 2026 guidance targets at least 18% revenue growth, with gross margin stability and continued investment in commercial and R&D initiatives.
AxoGen reports Q4 adjusted EPS 7c, consensus 10c
Reports Q4 revenue $59.9M, consensus $59.9M. “2025 was a remarkable year of financial and operational achievement for Axogen (AXGN), as we attained or progressed every objective expected of our strate...
AxoGen sees FY26 revenue $265.7M, consensus $259.53M
The company said, “We expect 2026 revenue growth to be at least 18%, or $265.7M, for the full-year and gross margin to be in the range of 74% to 76%.
AxoGen price target raised to $42 from $34 at Citizens
Citizens raised the firm’s price target on AxoGen (AXGN) to $42 from $34 and keeps an Outperform rating on the shares. In December, AxoGen’s Avance Nerve Graft received FDA BLA…
AxoGen price target raised to $41 from $36 at Raymond James
Raymond James analyst Jayson Bedford raised the firm’s price target on AxoGen (AXGN) to $41 from $36 and keeps an Outperform rating on the shares. AxoGen stands out as a…
AxoGen initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of AxoGen (AXGN) with an Overweight rating and $40 price target The firm says AxoGen is the only company fully focused on the treatment of peripheral…
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...